PhaseRx, Inc.
PZRXQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.17K
Close$
Share Statistics
| Market cap | $1,169.00 |
|---|---|
| Enterprise Value | $185,169.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.68 |
| Beta | -2.55 |
| Outstanding Shares | 11,690,000 |
Return
| Return on Equity | 4614.95% |
|---|---|
| Return on Assets | -230.06% |
| Return on Invested Capital | -391.18% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.01 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 29.38 |
| Debt to Equity | -18.08 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About PhaseRx, Inc.
10 employees
CEO: Dr. Robert W. Overell Ph.D. PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products b...